Tirzepatide for obstructive sleep apnea: what SURMOUNT-OSA actually showed

Key takeaways

• SURMOUNT-OSA (Malhotra 2024 NEJM) randomized 469 adults with moderate-to-severe OSA and obesity (BMI greater than or equal to 30, AHI greater than or equal to 15) into two parallel trials: trial 1 in PAP-naive patients, trial 2 in patients on stable PAP therapy .
• Tirzepatide produced a mean reduction in AHI of approximately 25 events per hour in trial 1 and 29 events per hour in trial 2, versus 5 and 6 events per hour respectively on placebo, over 52 weeks.
• Concurrent reductions: body weight (about 18 to 20 percent), hypoxic burden, hsCRP, and systolic blood pressure all improved on tirzepatide versus placebo.
• FDA approved Zepbound (tirzepatide) for moderate-to-severe OSA in adults with obesity on 2024-12-20, the first medication indication for OSA .
• AHI reductions of this magnitude are clinically meaningful but the trials did not power for hard outcomes (cardiovascular events, mortality, motor-vehicle accidents); long-term outcome data are pending.
• Tirzepatide is not a substitute for PAP therapy in patients with severe OSA or significant daytime symptoms; the FDA labeling and AASM commentary frame it as a complementary or alternative option, not a wholesale replacement.

What is OSA and why does obesity matter

Obstructive sleep apnea is recurrent partial or complete upper-airway collapse during sleep, producing fragmented sleep, intermittent hypoxia, and sympathetic activation. The standard severity metric is the apnea-hypopnea index (AHI), the count of obstructive events per hour. Mild OSA is 5 to less than 15, moderate is 15 to less than 30, and severe is 30 or higher.

Obesity is the strongest modifiable risk factor for OSA. Adipose deposition around the upper airway, increased neck circumference, and reduced lung volume during supine sleep all contribute. Surgical and intensive-lifestyle weight loss have been shown to reduce AHI; the question SURMOUNT-OSA addressed was whether pharmacologic weight loss with a GLP-1 plus GIP co-agonist would do the same.

Trial design

SURMOUNT-OSA was published as a single paper covering two parallel phase 3, double-blind, placebo-controlled trials in adults with moderate-to-severe OSA (AHI greater than or equal to 15) and obesity (BMI greater than or equal to 30). Trial 1 enrolled 234 patients who were not using PAP therapy at baseline. Trial 2 enrolled 235 patients who were on stable PAP therapy at baseline and continued PAP throughout the trial. Both trials used maximum-tolerated tirzepatide (10 or 15 mg subcutaneously once weekly) versus matching placebo for 52 weeks .

The primary endpoint was change in AHI from baseline to week 52, measured by polysomnography. Secondary endpoints included percent change in body weight, hypoxic burden (a composite reflecting both depth and duration of desaturation events), high-sensitivity C-reactive protein (hsCRP) as a marker of systemic inflammation, systolic blood pressure, and patient-reported outcomes including the Patient-Reported Outcomes Measurement Information System (PROMIS) sleep disturbance and sleep-related impairment scales.

What the trial found

In trial 1 (PAP-naive), tirzepatide reduced mean AHI by 25.3 events per hour from a baseline of about 51, versus a 5.3-event-per-hour reduction on placebo. In trial 2 (on PAP), tirzepatide reduced mean AHI by 29.3 events per hour from a baseline of about 65, versus 5.5 events per hour on placebo. Both trials showed statistically significant separation from placebo at week 52.

Body weight fell by approximately 18 percent (trial 1) and 20 percent (trial 2) on tirzepatide versus 1.6 to 2.3 percent on placebo. Hypoxic burden was reduced. hsCRP fell by 35 to 50 percent on tirzepatide. Systolic blood pressure fell by approximately 6 to 9 mm Hg. Patient-reported sleep symptoms improved versus placebo.

FDA label change and prescribing context

On 2024-12-20 the FDA approved Zepbound (tirzepatide) for moderate-to-severe OSA in adults with obesity, in conjunction with a reduced-calorie diet and increased physical activity. This was the first FDA-approved drug specifically indicated for OSA .

Practical implications: a patient with documented moderate-to-severe OSA (AHI greater than or equal to 15) and obesity (BMI greater than or equal to 30) now has a labeled pharmacologic option for the OSA indication, distinct from the obesity indication that already existed. Coverage logic for sleep medicine differs from coverage logic for obesity; payer pathways for OSA-indicated tirzepatide are still evolving in 2026.

American Academy of Sleep Medicine commentary has framed tirzepatide as an additional tool that does not displace PAP as the standard-of-care first-line therapy for symptomatic moderate-to-severe OSA. Patients with significant daytime sleepiness, motor-vehicle-accident risk, or severe OSA should still be evaluated for PAP. Pharmacologic weight loss is most appropriate as either an adjunct to PAP or an alternative for PAP-intolerant patients .

What the trial did not power for

• Cardiovascular hard outcomes (myocardial infarction, stroke, cardiovascular death). The mechanistic case for benefit (lower AHI, lower hypoxic burden, lower hsCRP, lower systolic BP) is strong, but the trial was not event-driven and follow-up was 52 weeks.
• Mortality.
• Motor-vehicle accidents and occupational-safety endpoints, which are tied to symptomatic OSA more than to AHI alone.
• Whether AHI improvement persists after discontinuation. Trial protocols required ongoing therapy.
• Pediatric OSA, central sleep apnea, or non-obese OSA. The trial was strictly moderate-to-severe OSA in obesity.
• Head-to-head comparison with semaglutide 2.4 mg, which has not been tested in a published OSA-specific trial.

The combined cardiometabolic picture

SURMOUNT-OSA fits into a wider 2023 to 2024 GLP-1 evidence picture: SELECT (cardiovascular outcomes in obesity without diabetes), STEP-HFpEF (heart failure with preserved ejection fraction with obesity), FLOW (kidney outcomes in T2D plus CKD), and SURMOUNT-OSA (obstructive sleep apnea). Each trial extends the cardiometabolic case independently. The question is no longer whether GLP-1 receptor agonists are weight-loss drugs that happen to help glucose; it is whether they are multi-organ-protective drugs whose obesity indication is now one of several.

For users of pepSmart already tracking dose, weight, and symptoms on an obesity indication, the SURMOUNT-OSA finding is most relevant if there is a parallel sleep complaint (snoring, witnessed apnea, daytime sleepiness, AHI on a home or in-lab study). A clinician conversation about the OSA-specific indication is reasonable in that case.

Editorial summary

SURMOUNT-OSA is the largest and most rigorous trial to date showing that pharmacologic weight loss with a GLP-1 plus GIP co-agonist reduces AHI and improves sleep-disordered-breathing biomarkers. The FDA labeling change followed quickly. The remaining clinical questions are about hard outcomes, durability, and how the AHI improvement integrates with the existing PAP standard of care. None of those gaps invalidate the trial; they just bound what it can claim.